Skip to contentI
Interpace Biosciences, Inc.
I
IDXGInterpace Biosciences, Inc. Q1 2020 · 10-Q
Revenue$9.06M$9.06M+50.7% vs Q1 2019 Net Income-$6.49M-$6.49MN/M vs Q1 2019 EPS Diluted-$2.38-$2.38N/M vs Q1 2019 Gross Profit$2,946,000−13.0% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Interpace Biosciences, Inc. · CIK 1054102 · Engraved from SEC EDGAR
Operating Cash Flow-$7,122,000N/M Margins · derivedGross margin32.5%−23.9 pt vs Q1 2019
Operating margin-70.1%−17.2 pt vs Q1 2019
Net margin-71.7%−16.3 pt vs Q1 2019
ended Mar 31, 2020 · filed Jun 26, 2020 · 87 d after period end